Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DENV2 NS1 mRNA-LNP vaccine
- Development stage
- Preclinical
- Lead developer
- University of Pennsylvania
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
DENV2 NS1 mRNA-LNP vaccine is an experimental mRNA-based vaccine candidate designed to protect against Dengue virus serotype 2 (DENV2) infection. Developed through a collaboration between the Yale School of Medicine and the University of Pennsylvania, the vaccine is formulated with lipid nanoparticles (LNPs) and encodes the non-structural protein 1 (NS1) of DENV2. Unlike traditional live-attenuated dengue vaccines that target structural proteins and carry a risk of inducing antibody-dependent enhancement (ADE) upon secondary infection, this vaccine induces non-neutralizing anti-NS1 antibodies. These antibodies protect against severe disease and vascular leakage while evading ADE, offering a safer vaccination strategy against lethal dengue challenge.
- Other names
- DENV2 NS1 mRNA-LNPDENV-2 NS1 mRNA-LNPDENV 2 NS1 mRNA-LNPNS1-based dengue vaccineNS-1-based dengue vaccineNS 1-based dengue vaccine
Beyond the preview
Go deeper on DENV2 NS1 mRNA-LNP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DENV2 NS1 mRNA-LNP vaccine.